ClinicalTrialsFinder

Triple-Negative Breast Cancer Clinical Trials in Chicago, Illinois

13 recruitingChicago, Illinois

Showing 1–13 of 13 trials

Recruiting
Phase 1

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 3

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled350 locationsNCT05633654
Recruiting
Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 1

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled33 locationsNCT06465069
Recruiting
Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 2

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Breast CancerTriple-Negative Breast CancerCirculating Tumor DNA+1 more
Dana-Farber Cancer Institute40 enrolled7 locationsNCT04434040
Recruiting
Phase 2

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Breast CancerTriple-Negative Breast CancerPD-L1 Negative
Dana-Farber Cancer Institute110 enrolled15 locationsNCT04468061
Recruiting
Phase 1

A Study of XMT-1660 in Participants With Solid Tumors

Breast CancerTriple-Negative Breast CancerOvarian Cancer+4 more
Mersana Therapeutics319 enrolled26 locationsNCT05377996
Recruiting
Phase 1

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.52 enrolled6 locationsNCT06908928
Recruiting
Phase 1

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Breast CancerTriple-Negative Breast CancerEsophageal Cancer+9 more
SystImmune Inc.470 enrolled39 locationsNCT05983432
Recruiting
Phase 1

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Triple-Negative Breast Cancer
University of Illinois at Chicago12 enrolled1 locationNCT04427293
Recruiting
Phase 1

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Triple-Negative Breast CancerColorectal CarcinomaNon-small Cell Lung Cancer+4 more
Janux Therapeutics130 enrolled18 locationsNCT05783622
Recruiting
Phase 1

PRE-I-SPY Phase I/Ib Oncology Platform Program

Triple-Negative Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+18 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226